CION Ameerpet
Pancreatic Cancer · Diagnosis & Tests · Reviewed by CION Oncologists
DOTATATE PET-CT for neuroendocrine tumours — what the scan actually shows
A DOTATATE PET-CT does not look for cancer in general. It looks for somatostatin receptors — the marker that well-differentiated neuroendocrine tumours carry and most other tumours do not. This page explains what that means for the result you are holding.
- It looks for receptors, not sugar — which is why a slow neuroendocrine tumour shows here and often not on a standard PET-CT.
- Not a general cancer scan — it is ordered when a neuroendocrine tumour is suspected or confirmed, not for every pancreatic mass.
- A quiet scan is not an all-clear — some tumours lose their receptors, so the result is always read with your CT, MRI and biopsy.
- Coordinated, not in-house — CION arranges the scan with partner nuclear-medicine centres and reads it into your plan.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres Across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What a DOTATATE PET-CT Actually Shows
A DOTATATE PET-CT — written in some reports as DOTATATE PET CT, and often called a gallium DOTATATE scan — is a nuclear-medicine scan that looks for one specific thing: somatostatin receptors sitting on the surface of tumour cells. Well-differentiated neuroendocrine tumours carry these receptors in unusually large numbers. A small amount of a receptor-binding tracer is injected, it attaches to those receptors wherever they are in the body, and the scanner maps where it has collected.
That is a different question from the one a standard PET-CT asks. A standard scan uses a glucose-analogue tracer and shows where cells are burning sugar fast — genuinely useful in an aggressive cancer, much less so in a slow, well-differentiated neuroendocrine tumour, which can look almost invisible on it. The wider indication is covered separately in PET-CT in pancreatic cancer — when it is used.
So this is not a general cancer scan, and it is not ordered for every pancreatic mass. It is ordered when a pancreatic neuroendocrine tumour is suspected or already confirmed. That is a different disease from the far more common pancreatic ductal adenocarcinoma, with a different course and a materially better outlook, and the two are not managed the same way. If that distinction is new to you, begin with pancreatic neuroendocrine tumours (PNET) explained.
One consequence is worth saying plainly rather than burying. A tumour that does not carry somatostatin receptors will not light up, and a quiet scan is not by itself an all-clear — it means this particular test could not see anything, not that there is nothing to see. Higher-grade, less well-differentiated tumours frequently lose receptor expression as they become more aggressive, which is exactly when a glucose-based scan may show what this one does not. A DOTATATE PET-CT is read alongside your CT or MRI, your blood results and your biopsy. It is never read on its own.
Did you know? Somatostatin-receptor PET imaging, of which the DOTATATE study is the most widely used form, is named in NCCN guidance for neuroendocrine and adrenal tumours as the preferred functional imaging test for well-differentiated disease. It has largely displaced the older receptor scintigraphy scan that radiologists relied on for decades, because it resolves smaller deposits and is completed in a single visit rather than over repeated days. Whether the scan is the right one to order at all is decided by grade and differentiation, using the World Health Organization classification of neuroendocrine neoplasms — the framework that separates a well-differentiated neuroendocrine tumour from a poorly differentiated neuroendocrine carcinoma, which behaves quite differently and is imaged differently.
Why it gets ordered
The Questions This Scan Is Actually Asked to Answer
A scan is only worth doing if the answer changes something. These are the situations where it usually does.
Finding the primary
When the spread was found before the source
Some neuroendocrine tumours announce themselves through a hormone syndrome or a liver deposit long before the primary is located. Receptor imaging can show a small pancreatic primary that a good CT has already looked at and missed.
Mapping spread
Where else receptors are lighting up
The whole body is covered in one pass, so deposits in lymph nodes, liver or bone can appear in places a pancreatic-protocol CT was never aimed at. That can change the stage, and with it the plan.
Receptor status
Whether receptor-directed treatment is open to you
A tumour that binds the tracer strongly has receptors that can also be used therapeutically. This scan is the gateway to receptor-targeted radionuclide therapy, PRRT, which is coordinated with partner nuclear-medicine centres.
An unclear lesion
When CT cannot say what something is
An indeterminate pancreatic lesion that binds the tracer avidly behaves very differently from one that stays quiet. The result can change the working diagnosis rather than simply add a page to the file.
Follow-up
Restaging, or a suspected recurrence
A changing marker or a new symptom in someone already treated is a common reason to repeat the study — to establish whether anything has come back, and if so, where.
Planning
Feeding the tumour board, not a folder
The images come back to your oncologist and are weighed with pathology and CT before any plan is confirmed, alongside the options set out in pancreatic cancer treatment in Hyderabad.
How it fits with your other scans
DOTATATE PET-CT Next to the Scans You Already Have
These tests are not alternatives competing for the same job. Each answers a question the others cannot.
| Scan | What it is looking for | Where it helps most | Where it is done |
|---|---|---|---|
| DOTATATE PET-CT | Somatostatin receptors on tumour cells, anywhere in the body | Well-differentiated neuroendocrine tumours: finding an unknown primary, mapping spread, checking receptor status | Coordinated with a partner nuclear-medicine centre |
| Standard PET-CT | Cells consuming sugar unusually fast | Aggressive or higher-grade disease, including tumours that have lost their receptors | Coordinated with a partner nuclear-medicine centre |
| Pancreatic-protocol CT | Anatomy, and the tumour's relationship to the arteries and veins behind the pancreas | Deciding whether an operation is possible; the backbone of staging | Ordered and reported by CION |
| MRI / MRCP | Soft-tissue detail, the pancreatic and bile ducts, small liver lesions | Characterising a lesion the CT could not settle, and liver assessment | Ordered and reported by CION |
If you have been offered this scan and are not sure it is the right one, bring the reports and the discs, not just the summary letter. A free 45-minute consultation is usually enough to tell you whether it will change anything. Book a free consultation or call 1800 202 8726.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
One Scan Rarely Decides Anything On Its Own
Receptor imaging is read with your CT, your bloods and your biopsy. We put the whole picture together.
What actually happens
How the Scan Is Arranged, and Who Does What
-
The decision is made at CION
Your oncologist works out whether receptor imaging would change anything, using your biopsy result, the tumour grade and the scans you already have. If it would not change the plan, we will say so rather than order it.
In-house at CION -
The scan is booked at a partner centre
This study needs a licensed nuclear-medicine unit and a tracer that is prepared on the day. CION does not run one, and we would rather tell you that than blur it. We arrange the appointment with a partner nuclear-medicine centre, and that part of your care is billed there.
Coordinated with a partner nuclear-medicine centre -
Preparation is confirmed with you
The centre will tell you what to do about food and fluids beforehand, and will check the timing of any injectable somatostatin-analogue-class treatment you are already on, because that can compete with the tracer for the same receptors. Take your previous scans with you.
Coordinated with a partner nuclear-medicine centre -
The day itself
The tracer is injected, there is a wait while it binds to receptors, and then the scan, which asks only that you lie still. Most people are at the centre for a few hours in total and go home the same day. You are not admitted and you do not need someone to drive you.
Coordinated with a partner nuclear-medicine centre -
The images come back to your oncologist
We read them against your CT or MRI and your pathology, and take the case to a tumour board rather than acting on one report in isolation. The general pathway is set out on our PET-CT scan page.
In-house at CION -
What it means is explained to you in person
An avid scan is not a diagnosis on its own, and a quiet one is not a discharge. You get the finding, what it changes, what it does not change, and the next step, said in plain language and written down.
In-house at CION
Being straight about it
What CION Does, and What Is Coordinated Elsewhere
This matters practically, because it decides where you travel and who invoices you. CION does not have its own nuclear-medicine unit. DOTATATE PET-CT, standard PET-CT and receptor-targeted radionuclide therapy are all coordinated with partner nuclear-medicine centres, and those parts of your care may be billed by them rather than by us. In the same way, endoscopic ultrasound and biopsy, ERCP and any biliary or duodenal stenting, staging laparoscopy, coeliac plexus block and all pancreatic surgery are coordinated with specialist hepatobiliary, gastroenterology and endoscopy partners.
What happens at CION is everything around the scan, and on a neuroendocrine pathway that is most of the journey. The decision to order it. The reading of it against the rest of your imaging. The tumour board. Systemic treatment for a neuroendocrine tumour, including somatostatin-analogue-class therapy, delivered in-house across 35+ centres. Pancreatic-protocol CT, MRI and MRCP, CA 19-9 and routine bloods. Genetic counselling where the history warrants it, nutrition and pancreatic enzyme support, pain and psycho-oncology care, and long-term follow-up once treatment settles.
- A free 45-minute consultation, with your scans opened and read in front of you rather than summarised back to you from a report.
- A straight answer on whether a DOTATATE PET-CT would change your management — and if it would not, we will tell you that instead of adding a test.
- A written split of what the partner centre bills and what CION bills, before anything is booked.
- Aarogyasri, NTR Vaidya Seva and insurance routes checked against each part of the pathway, not just the treatment.
- Systemic therapy, radiation where it is appropriate, nutrition and supportive care delivered in-house — the options are set out in pancreatic cancer treatment in Hyderabad.
- The whole picture in one place, in our complete guide to pancreatic cancer.
Bring the discs as well as the printed reports, and bring the biopsy report if you have it. Those three together are usually enough for a specialist to tell you where you stand. Book a free consultation or call 1800 202 8726.
Take the next step
Understand the Scan Before You Have It
Knowing what a test can and cannot answer takes a good deal of the fear out of waiting for it.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
DOTATATE PET-CT — your questions answered
What does a DOTATATE PET-CT actually look for?
It looks for somatostatin receptors, which are proteins that sit on the surface of neuroendocrine tumour cells in unusually large numbers. A small quantity of a receptor-binding tracer is injected into a vein, it attaches to those receptors wherever they happen to be in the body, and the scanner maps where it has gathered. Areas that bind the tracer strongly show up clearly against everything else. Because the study covers the whole body in a single pass, it can show a small primary tumour in the pancreas and, at the same time, any deposits in lymph nodes, the liver or bone. The CT part of the same appointment supplies the anatomy, so that a bright area can be matched to a precise location rather than a rough region.
How is it different from an ordinary PET-CT scan?
They ask different questions. An ordinary PET-CT uses a glucose-analogue tracer and shows where cells are burning sugar quickly, which suits an aggressive, fast-dividing cancer. A well-differentiated neuroendocrine tumour often grows slowly and does not consume sugar in that way, so it can look almost invisible on a standard study while being obvious on a receptor scan. The reverse is also true: a higher-grade tumour that has lost its receptors may be quiet on the receptor scan and clear on the sugar-based one. That is why the two are not interchangeable, and why some people end up having both. Which one is right for you depends on the grade and differentiation of your tumour, which comes from the biopsy rather than from any scan.
Does a quiet DOTATATE PET-CT mean I do not have a tumour?
No, and this is the single most important thing to understand about the test. A quiet scan means this particular study could not see receptor-rich tissue. It does not mean nothing is there. Tumours that are higher grade or less well differentiated frequently lose receptor expression as they become more aggressive, and those are precisely the tumours that may show on a glucose-based scan instead. Very small deposits can also fall below what any scanner can resolve. For that reason the result is always read alongside your CT or MRI, your blood results and your biopsy, and never treated as a verdict on its own. If the picture does not hang together, the right response is another look, not reassurance.
My biopsy already confirmed a neuroendocrine tumour. Why would I still need this scan?
A biopsy tells you what the tumour is. This scan helps tell you where it is and what can be done about it. It can find deposits outside the field a pancreatic CT was aimed at, which sometimes changes the stage and therefore the plan. It also shows whether the tumour binds the tracer strongly, and that matters because receptors that can be imaged can in some cases be targeted therapeutically, through receptor-directed radionuclide treatment. It gives a baseline to compare future scans against. And where a primary has never been located, it is often the study that finds it. If none of those questions apply to your situation, the scan may add nothing, and we will say so.
What happens on the day, and is the scan safe?
The tracer is given through a vein, there is a waiting period while it binds to receptors, and then the scan itself, which needs you to lie still and is quieter than an MRI. Most people are at the centre for a few hours in total, go home the same day, and are not admitted. There is a radiation exposure, as with any nuclear-medicine study, and the tracer clears from the body over the hours afterwards; staff will tell you about contact with young children or anyone pregnant. Reactions to the tracer itself are uncommon. Tell the centre if you are pregnant or breastfeeding, and tell them about any injectable somatostatin-analogue-class treatment you are on, because its timing can affect the images.
What does CION do for this, and what happens at the first visit?
CION does not run its own nuclear-medicine unit. The DOTATATE PET-CT, any standard PET-CT and receptor-targeted radionuclide therapy are coordinated with partner nuclear-medicine centres and may be billed there. What we do is decide whether the scan is worth doing, arrange it, read it against the rest of your imaging, and act on it. The first appointment is a free 45-minute consultation. Bring your scan discs rather than only the printed reports, and your biopsy report if you have one. Your scans are opened and read in front of you, you are told plainly what is known and what is not, and you leave with a written next step and a clear split of what a partner centre would bill and what CION would bill.
Medical disclaimer: This page explains what a DOTATATE PET-CT looks for in pancreatic neuroendocrine tumours and how the study fits with the rest of the imaging pathway, and is reviewed by a CION medical oncologist with reference to NCCN guidance on neuroendocrine and adrenal tumours and the World Health Organization classification of neuroendocrine neoplasms. It is general information and not a substitute for an individual radiological or oncological opinion; whether this scan is appropriate for you depends on your own histology, grade and prior imaging, and must be decided with your treating team. Pancreatic-protocol CT, MRI and MRCP, CA 19-9 and bloods, tumour-board planning, systemic therapy for neuroendocrine tumours including somatostatin-analogue-class treatment, chemotherapy, radiation and SBRT, genetic counselling, nutrition and pancreatic enzyme support, pain and psycho-oncology care and survivorship follow-up are delivered by CION. DOTATATE PET-CT, standard PET-CT and receptor-targeted radionuclide therapy are coordinated with partner nuclear-medicine centres, and endoscopic ultrasound and biopsy, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block and all pancreatic surgery are coordinated with specialist hepatobiliary, gastroenterology and endoscopy partner centres; each of these may be billed there.